SCOPUS 정보 검색 플랫폼

Current Diabetes Reports

Volumn 11, Issue 1, 2011, Pages 4-6

Cardiovascular risk reduction via increasing HDL cholesterol: The promise of the dal-OUTCOMES trial

(6) Soe, Kyaw a Alam, Anis a Philip, Charles a Ruiz, Edison a Ramkissoon, Keshwar a McFarlane, Samy I a

a KINGS COUNTY HOSPITAL CENTER (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALCETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; OUTCOME ASSESSMENT; RISK REDUCTION; TREATMENT DURATION;

EID: 79551535148 PISSN: 15344827 EISSN: None Source Type: Journal
DOI: 10.1007/s11892-010-0165-8 Document Type: Article

Times cited : (1)

References (9)

1
- 0027994593
- Established risk factors and coronary artery disease: The Framingham Study
- PW Wilson 1991 Established risk factors and coronary artery disease: the Framingham Study Am J Hypertens 7 7S
- (1991) Am J Hypertens , vol.7
- Wilson, P.W.¹

2
- 0023029454
- Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study
- DOI 10.1001/jama.256.20.2835
- WP Castelli RJ Garrison PW Wilson, et al. 1986 Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study JAMA 256 20 2835 2838 1:STN:280:DyaL2s%2FjslWktA%3D%3D 10.1001/jama.256.20.2835 3773200 (Pubitemid 17178361)
- (1986) Journal of the American Medical Association , vol.256 , Issue.20 , pp. 2835-2838
- Castelli, W.P.¹ Garrison, R.J.² Wilson, P.W.F.³

3
- 0027275449
- Plasma cholesteryl ester transfer protein
- 1:CAS:528:DyaK3sXmt1agtr4%3D 8409761
- AR Tall 1993 Plasma cholesteryl ester transfer protein J Lipid Res 34 1255 74 1:CAS:528:DyaK3sXmt1agtr4%3D 8409761
- (1993) J Lipid Res , vol.34 , pp. 1255-74
- Tall, A.R.¹

4
- 0024415898
- Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins
- DOI 10.1038/342448a0
- ML Brown A Inazu CB Hesler, et al. 1989 Molecular basis of lipid transfer protein deficiency in a family with increased highdensity lipoproteins Nature 342 448 51 1:CAS:528:DyaK3cXltlaktw%3D%3D 10.1038/342448a0 2586614 (Pubitemid 19277523)
- (1989) Nature , vol.342 , Issue.6248 , pp. 448-451
- Brown, M.L.¹ Inazu, A.² Hesler, C.B.³ Agellon, L.B.⁴ Mann, C.⁵ Whitlock, M.E.⁶ Marcel, Y.L.⁷ Milne, R.W.⁸ Koizumi, J.⁹ Mabuchi, H.¹⁰ Takeda, R.¹¹ Tall, A.R.¹²

5
- 36348975228
- Effects of torcetrapib in patients at high risk for coronary events
- DOI 10.1056/NEJMoa0706628
- PJ Barter S Nicholls KA Rye, et al. 2007 ILLUMINATE investigators. Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 21 2109 22 1:CAS:528:DC%2BD2sXhtlGns7bL 10.1056/NEJMoa0706628 17984165 (Pubitemid 350146106)
- (2007) New England Journal of Medicine , vol.357 , Issue.21 , pp. 2109-2122
- Barter, P.J.¹ Caulfield, M.² Eriksson, M.³ Grundy, S.M.⁴ Kastelein, J.J.P.⁵ Komajda, M.⁶ Lopez-Sendon, J.⁷ Mosca, L.⁸ Tardif, J.-C.⁹ Waters, D.D.¹⁰ Shear, C.L.¹¹ Revkin, J.H.¹² Buhr, K.A.¹³ Fisher, M.R.¹⁴ Tall, A.R.¹⁵ Brewer, B.¹⁶

6
- 48149106322
- Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone
- 1:CAS:528:DC%2BD1cXptVajs7g%3D 10.1038/bjp.2008.229 18536749
- MJ Forrest D Bloomfield RJ Briscoe, et al. 2008 Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone Br J Pharmacol 154 1465 1473 1:CAS:528:DC%2BD1cXptVajs7g%3D 10.1038/bjp.2008.229 18536749
- (2008) Br J Pharmacol , vol.154 , pp. 1465-1473
- Forrest, M.J.¹ Bloomfield, D.² Briscoe, R.J.³

7
- 67649304458
- Safety and tolerability of dalcetrapib
- 1:CAS:528:DC%2BD1MXotFCitL8%3D 10.1016/j.amjcard.2009.02.061
- EA Stein ESG Stroes G Steiner, et al. 2009 Safety and tolerability of dalcetrapib AmJ Cardiol 104 82 91 1:CAS:528:DC%2BD1MXotFCitL8%3D 10.1016/j.amjcard.2009.02.061
- (2009) AmJ Cardiol , vol.104 , pp. 82-91
- Stein, E.A.¹ Stroes, E.S.G.² Steiner, G.³

8
- 38749102779
- High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk. The IDEAL and EPIC-Norfolk Studies
- DOI 10.1016/j.jacc.2007.09.060, PII S0735109707036790
- WA Van Der Steeg I Holme SM Boekholdt, et al. 2008 High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: Significance for cardiovascular risk: The IDEAL and EPIC-Norfolk studies J Am Coll Cardiol 51 634 642 10.1016/j.jacc.2007.09.060 18261682 (Pubitemid 351186873)
- (2008) Journal of the American College of Cardiology , vol.51 , Issue.6 , pp. 634-642
- Van Der Steeg, W.A.¹ Holme, I.² Boekholdt, S.M.³ Larsen, M.L.⁴ Lindahl, C.⁵ Stroes, E.S.G.⁶ Tikkanen, M.J.⁷ Wareham, N.J.⁸ Faergeman, O.⁹ Olsson, A.G.¹⁰ Pedersen, T.R.¹¹ Khaw, K.-T.¹² Kastelein, J.J.P.¹³

9
- 33748422658
- High-density lipoprotein: Is it always atheroprotective?
- DOI 10.1007/s11883-006-0038-4
- BJ Ansell GC Fonarow AM Fogelman 2006 Highdensity lipoprotein: is it always atheroprotective? Curr Atheroscler Rep 8 5 405 411 1:CAS:528: DC%2BD28XpslagsrY%3D 10.1007/s11883-006-0038-4 16901411 (Pubitemid 44340185)
- (2006) Current Atherosclerosis Reports , vol.8 , Issue.5 , pp. 405-411
- Ansell, B.J.¹ Fonarow, G.C.² Fogelman, A.M.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.